ClinicalTrials.gg
RecruitingNCT06527521APTURUpdated Oct 27, 2026

Prevalence of Amyloidosis in Trauma Patients

An observational study in Amyloidosis, sponsored by Consorci Sanitari de l'Alt Penedès i Garraf. Recruiting at 1 site in Spain. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Consorci Sanitari de l'Alt Penedès i Garraf · Observational

From the registry’s dates

  • Started Nov 2024; still recruiting 1 year 11 months later.
Updated Oct 27, 2026Primary completion movedStudy completion movedGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
246
Sex
All
01

Study summary

This study aims to determine the frequency of amyloidosis among patients undergoing trauma surgery.

02

Conditions studied

  • Amyloidosis

Browse trials for

Keywords

  • Amyloidosis
  • Red Flags tool
  • Traumatology
03

In context

Amyloidosis

290 studies on the registry are indexed under Amyloidosis; 92 are open to participants now.

This study's planned enrollment of 246 is above the median of 190 across 83 observational studies indexed under Amyloidosis.

Browse Amyloidosis studies →

Lead sponsor

Consorci Sanitari de l'Alt Penedès i Garraf is the lead sponsor of 41 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients included in the waiting list for scheduled trauma surgery

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women included in the waiting list for scheduled trauma surgery with at least one of the following criteria defined as red flags: Over 65 years old; Possible family history of amyloidosis, Cardiac pathology: aortic stenosis, presence of left ventricular hypertrophy defined as interventricular septal thickness > 12mm measured by echocardiography, history of previous brady- or tachyarrhythmias including cardiac conduction blocks, history of syncope or presyncope, pro BNP > 300 in previous blood tests; History of sensory peripheral neuropathy; History of nephropathy without etiological diagnosis; History of liver disease without a clear cause.
  • Ability to cooperate in the necessary evaluations.
  • Signed for inclusion in the study, either by the participant or their legal representative.

Exclusion criteria

Exclusion Criteria:

- Participants previously diagnosed with amyloidosis cannot be included in the study.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
246 participants (estimated)
Patient registry
No

Interventions

  • ProcedureTraumatologic surgery

    Patients undergoing trauma surgery

06

What researchers measure

Primary outcomes

  1. Amyloidosis

    Proportion of patients undergoing scheduled orthopedic surgery who are diagnosed with amyloidosis.

    Time frame: One month

07

Study locations

1 of 1 sites recruiting
  • Consorci Sanitari Alt Penedes i Garraf-Hospital Sant Camil
    Sant Pere de Ribes, Barcelona 08810, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — IPD (without personal identification data) could be shared by requirement from other researchers after the end of the study, and only for research purposes and previous approval of promotor center of the study (CSAPG). Anyway, Spanish and European Union legal policy about data protection will strictly be followed (IPD will not be transferred outside European Union).

Supporting information: Study protocol, Informed consent form

Time frame: After publication of main results of the study.

Access criteria: IPD will be shared only for scientific research purposes and following the Spanish and European Union normative law about data protection. The requirements will be directed to the IP of the study. The IP will evaluate the request to verify and evaluate the data that is requested and the purposes for which it is requested. Next, the IP will transfer the request to the promotor center the study for the final decision.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Nov 2024 (actual). Primary completion is estimated for Aug 2027, 33 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Aug 2026 → Aug 2027 and completion Oct 2026 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2024
First posted
Jul 30, 2024
StartActual
Nov 13, 2024
Primary completionEst.
Aug 2027was Aug 2026
CompletionEst.
Oct 2027was Oct 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 2026→Aug 2027
Oct 27, 2026
Study completion
Oct 2026→Oct 2027
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Primary completion Aug 2026→Aug 2027
    Study completion Oct 2026→Oct 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06527521
Lead sponsor
Consorci Sanitari de l'Alt Penedès i Garraf
Responsible party
Sponsor
First posted
Jul 30, 2024
Start date
Nov 13, 2024
Primary completion
Aug 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Oct 27, 2026

Study contacts

Lidia Tikhomirova, MD
Contact
ltikhomirova@csapg.cat
+34 938960025
Noemí Casaponsa
Contact
recerca@csapg.cat
+34 938960025 ext. 43197
Lidia Tikhomirova, MD
principal investigator · CSAPG

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion